Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: manny t who wrote (7878)	6/10/1999 7:32:00 PM
From: John F. Dowd	Read Replies (3) \| Respond to of 9523

mannyt: What else is there lurking? Can these "pros" be that far off. Trovan produces nice but not blockbuster earnings as it is a last chance anti-biotic. 5 deaths in 2.5 mill. prescriptions when people are sick enough for Trovan is not unreasonable risk. There must be something else going on. JFD

To: manny t who wrote (7878)	6/11/1999 11:01:00 AM
From: Anthony Wong	Read Replies (1) \| Respond to of 9523

This Everen analyst has a price target of $149 (ST) and $165 (LT):: Pfizer Inc. Reiterated Short-Term 'Outperform' at Everen Bloomberg News June 11, 1999, 9:56 a.m. ET Princeton, New Jersey, June 11 (Bloomberg Data) -- Pfizer Inc. (PFE US) was reiterated short-term ''outperform'' by analyst Jeffrey J. Kraws at Everen Securities. The long-term rating was also reiterated ''outperform.'' The near-term and long- term price targets were also reiterated at $149 and $165, respectively.